Disease Free Survival - an overview | ScienceDirect Topics
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Kaplan–Meier Estimates of Event-free and Overall Survival among... | Download Scientific Diagram
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia | Nature Communications
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments - ScienceDirect
Predictors of Long-Term Outcome after Percutaneous Balloon Mitral Valvuloplasty | NEJM
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer | NEJM
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma | NEJM
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer | NEJM
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial - The Lancet Oncology
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments - ScienceDirect
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions | British Journal of Cancer
Event-free survival curves. The Kaplan-Meier curves demonstrate no... | Download Scientific Diagram
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Survival Analysis in Python (KM Estimate, Cox-PH and AFT Model) | by Rahul Raoniar | The Researchers' Guide | Medium
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia | Annals of Hematology
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
